tradingkey.logo

Evoke Pharma Inc

EVOK
View Detailed Chart
10.672USD
+0.012+0.12%
Market hours ETQuotes delayed by 15 min
15.93MMarket Cap
LossP/E TTM

Evoke Pharma Inc

10.672
+0.012+0.12%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.12%

5 Days

+117.80%

1 Month

+133.48%

6 Months

+245.39%

Year to Date

+141.46%

1 Year

+86.58%

View Detailed Chart

TradingKey Stock Score of Evoke Pharma Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Evoke Pharma Inc's Score

Industry at a Glance

Industry Ranking
63 / 159
Overall Ranking
170 / 4616
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
18.000
Target Price
+250.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Evoke Pharma Inc Highlights

StrengthsRisks
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 308.56% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.25M.
Undervalued
The company’s latest PE is -8.52, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 411.85K shares, increasing 3.73% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 8.31K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.17.

Evoke Pharma Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Evoke Pharma Inc Info

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
Ticker SymbolEVOK
CompanyEvoke Pharma Inc
CEOMr. Matthew J. (Matt) D'Onofrio
Websitehttps://evokepharma.com/
KeyAI